- 1.
- Botox® onabotulinumtoxinA for injection Ph. Eur. Clostridium botulinum type A neurotoxin complex (900kD); sterile vacuum-dried concentrate powder for solution for injection: 50, 100 and 200 Allergan units per vial [product monograph]. Markham (ON): Allergan, Inc; Dec 21, 2011.
- 2.
- CDEC final recommendation: onabotulinumtoxinA (Botox - Allergan Inc.). Indication: neurogenic detrusor overactivity [Internet]. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); Jul 19, 2012. [cited 2013 Dec 19]. Common Drug Review. Available from: http://www
.cadth.ca/media /cdr/complete/cdr _complete_Botox_July-23-12.pdf. - 3.
- Allergan Inc., comments on onabotulinumtoxinA clinical review and CDR reviewer's response [CONFIDENTIAL additional manufacturer's information]. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH); Feb, 2014. Allergan Inc., Canadian Agency for Drugs and Technologies in Health.
- 4.
- CDR submission binder: Botox (onabotulinumtoxinA for injection); New indication: chronic migraine; Company: Allergan [CONFIDENTIAL manufacturer's submission]. Markham (ON): Allergan Inc; Aug, 2013. Pharmacoeconomic evaluation.
- 5.
- Guidelines for the economic evaluation of health technologies: Canada [Internet]. 3rd ed. Ottawa: The Agency; Mar, 2006. [cited 2014 Apr 17]. Canadian Agency for Drugs and Technologies in Health. Available from: http://www
.cadth.ca/media /pdf/186_EconomicGuidelines_e.pdf. - 6.
- Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007 Jan;68(5):343–349. [PubMed: 17261680]
- 7.
- Lipton RB. Tracing transformation: chronic migraine classification, progression, and epidemiology. Neurology. 2009 Feb 3;72(5 Suppl):S3–S7. [PubMed: 19188564]
- 8.
- Batty AJ, Hansen RN, Bloudek LM, Varon SF, Hayward EJ, Pennington BW, et al. The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK. J Med Econ. 2013 Jul;16(7):877–887. [PubMed: 23647483]
- 9.
- Ruggeri M, Carletto A, Marchetti M. Cost-effectiveness of onabotulinumtoxin-a for the prophylaxis of chronic migraine [abstract]. Value Health; Presented at ISPOR 15th Annual European Congress; Berlin. November 3–7, 2012. Nov, 2012. p. A553.
- 10.
- Deiner HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007 Jul;27(7):814–823. [PubMed: 17441971]
- 11.
- Silberstein SD, Lipton RB, Dodick DW, Freitag F, Ramadan N, Matthew N, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007 Feb;47(2):170–180. [PubMed: 17300356]
- 12.
- Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010 Jun;50(6):921–936. [PubMed: 20487038]
- 13.
- Gillard PJ, Devine B, Varon SF, Liu L, Sullivan SD. Mapping from disease-specific measures to health-state utility values in individuals with migraine. Value Health. 2012;15(3):485–494. [PubMed: 22583459]
- 14.
- Sanderson JC, Devine EB, Lipton RB, Bloudek LM, Varon SF, Blumenfeld AM, et al. Headache-related health resource utilisation in chronic and episodic migraine across six countries. J Neurol Neurosurg Psychiatry [Internet] 2013 Dec;84(12):1309–1317. [cited 2013 Dec 19]; Available from: http://www
.ncbi.nlm.nih .gov/pmc/articles/PMC3841803. [PMC free article: PMC3841803] [PubMed: 23813744] - 15.
- Botulinum toxin type A for the prevention of headaches in adults with chronic migraine [Internet]. London: NICE; Jun, 2012. [cited 2013 Dec 19]. National Institute for Health and Clinical Excellence. (NICE technology appraisal guidance 260). Available from: http://www
.nice.org.uk /nicemedia/live/13776/59836/59836.pdf. - 16.
- Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011 Feb;31(3):301–315. [PubMed: 20813784]
- 17.
- Schedule of benefits for physician services under the Health Insurance Act: effective October 1, 2013 [Internet]. Toronto: The Ministry; 2013. [cited 2013 Dec 19]. Ontario Ministry of Health and Long-Term Care. Available from: http://www
.health.gov .on.ca/english/providers /program/ohip/sob /physserv/physserv_mn.html. - 18.
- Silberstein S, Tfelt-Hansen P, Dodick DW, Limmroth V, Lipton RB, Pascual J, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia. 2008 May;28(5):484–495. [PubMed: 18294250]
- 19.
- Pryse-Phillips WE, Dodick DW, Edmeads JG, Gawel MJ, Nelson RF, Purdy RA, et al. Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. CMAJ [Internet] 1997 May 1;156(9):1273–1287. [cited 2013 Dec 19]; Available from: http://www
.ncbi.nlm.nih .gov/pmc/articles/PMC1227329. [PMC free article: PMC1227329] [PubMed: 9145054] - 20.
- Pringsheim T, Davenport W, Mackie G, Worthington I, Aube M, Christie SN, et al. Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci [Internet] 2012 Mar;39(2 Suppl 2):S1–S59. [cited 2013 Dec 19]; Available from: http:
//headachenetwork .ca/wp-content/uploads /CanadianHeadacheSocietyGuidelineforMigraineProphylaxis .pdf. [PubMed: 22683887]
Publication Details
Copyright
Copyright © CADTH 2015.
You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.
Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Publisher
Canadian Agency for Drugs and Technologies in Health, Ottawa (ON)
NLM Citation
OnabotulinumtoxinA for Injection (Botox): For the Prophylaxis of Headaches in Adults With Chronic Migraine (≥ 15 Days per Month With Headache Lasting 4 Hours a Day or Longer) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Jul. REFERENCES.